Upside, Downside Movers in the Morning
Upside:
-AGPU +19% (signs more than $1.3B in new AI infrastructure contracts)
-KAPA +19% (partners with Bayer to evaluate ENV-105 plus Xofigo in bone-involving mCRPC)
-ARWR +18% (reports Phase 3 data for plozasiran in severe hypertriglyceridemia)
-SMCI +14% (prelim earnings metrics, guidance)
-OTLY +12% (earnings, guidance)
-FTAI +9.2% (awarded $1.5B order by international cloud service provider for Mod-1 mobile gas turbine generator sets)
-TONX +4.8% (highlights infrastructure upgrades)
-FLNC +4.4% (CitiGroup Raised FLNC to Buy from Neutral, price target: $24)
-CRSR +4.3% (ROTH Initiates CRSR with Buy, price target: $15)
-T +4.3% (earnings, guidance)
-SMMT +4.2% (reports updated Phase 3 OS data for ivonescimab in EGFR-mutated advanced non-squamous NSCLC)
-BLFS +2.8% (to be acquired by Repligen for $1.5B)
-WAB +2.5% (earnings, guidance)
-JOBY +2.1% (signs multi-year agreement with Virgin Atlantic for UK air taxi services)
-MNDY +2.1% (initiates restructuring plan affecting ~20% of workforce; raises FY26 op margin guidance)
-CSIQ +2.0% (CitiGroup Raised CSIQ to Neutral from Sell, price target: $18)
-RKLB +2.0% (awarded $266M US Air Force contract)
Downside:
-ADTN -20% (prelim earnings, guidance)
-PEGA -18% (earnings, color)
-CALM -6.6% (earnings, color)
-AIR -6.5% (earnings, guidance)
-GEV -6.4% (earnings, guidance)
-RDDT -6.4% (considers blocking Google from using content for AI)
-TEL -6.2% (earnings, guidance)
-BKU -5.9% (earnings, guidance)
-CLDX -5.4% (reports Phase 2 data for barzolvolimab in prurigo nodularis; Primary and key secondary endpoints not met)
-IONS -5.1% (lower off ARWR Phase 3 data for plozasiran in severe hypertriglyceridemia)
-ALK -3.6% (earnings, guidance)
-CB -3.6% (earnings, color)
-AMD -2.8% (signs major chips and investment agreement with Anthropic; to invest $5B)
Positions: None.
